Results 101 to 110 of about 14,336,962 (399)

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII

Molecular Therapy: Methods & Clinical Development, 2020
It is well known that canine factor VIII (cFVIII) has a higher specific activity than does human FVIII (hFVIII), and it has been previously demonstrated that cFVIII light chain is able to enhance hFVIII activity.
Jenni Firrman, Qizhao Wang, Wenman Wu, Biao Dong, Wenjing Cao, Andrea Rossi Moore, Sean Roberts, Barbara A. Konkle, Carol Miao, LinShu Liu, Dong Li, Weidong Xiao   +11 more
doaj  

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms

Haematologica, 2018
The development of inhibitory antibodies to factor VIII is the most serious complication of replacement therapy in hemophilia A. Activation of the innate immune system during exposure to this protein contributes to inhibitor development.
Maria T. Georgescu, Paul C. Moorehead, Alice S. van Velzen, Kate Nesbitt, Birgit M. Reipert, Katharina N. Steinitz, Maria Schuster, Christine Hough, David Lillicrap   +8 more
doaj   +1 more source

Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. [PDF]

, 2010
BACKGROUND: Coagulation factor VIII (FVIII) deficiency leads to haemophilia A. Conversely, elevated plasma levels are a strong predictor of recurrent venous thromboemboli and pulmonary hypertension phenotypes in which in situ thromboses are implicated ...
Angus, G, Birdsey, GM, Elderfield, K, Govani, FS, Laffan, MA, Manning, RA, Mauri, FA, Mollet, IG, Okoli, GN, Shovlin, CL   +9 more
core   +1 more source

Factor VIII Inhibitor with Catalytic Activity towards Factor VIII

, 2000
Hemophilia A is an X chromosome-linked recessive disorder resulting in defective or deficient factor VIII (FVIII) molecules, which, in its severe form, is a life-threatening, crippling hemorrhagic disease. Infusion of purified FVIII to patients with severe hemophilia A results in approximately 25% of the cases in the emergence of anti-FVIII antibodies (
Michael P. Horn, Sébastien Lacroix-Desmazes, S. V. Kaveri, Kazatchkine, Alexandre Moreau, Sooryanarayana   +5 more
openaire   +4 more sources

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

INDUCTION OF TOLERANCE BY ORAL ADMINISTRATION OF FACTOR VIII AND TREATMENT OF HEMOPHILA [PDF]

, 2011
Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a Subject a therapeutically effective amount of the deficient anti gen, wherein the antigen is not present in a liposome.
Alpan, Oral, Kamala, Tirumalai, Matzinger, Polly, Velander, William Hugold   +3 more
core   +1 more source

Immunogenicity of long-lasting recombinant factor VIII products [PDF]

, 2016
International audienceReplacement therapy for patients with hemophilia A using plasma-derived or recombinant factor VIII (FVIII) is complicated by the short half-life of the FVIII products and by the occurrence of neutralizing antibodies in a substantial
Delignat, Sandrine, Gupta, Nimesh, Ing, Mathieu, Lacroix-Desmazes, Sébastien, Maillère, Bernard, Pallardy, Marc, Teyssandier, Maud   +6 more
core   +4 more sources

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein

Journal of Thrombosis and Haemostasis, 2013
Summary.  Background: Hemophilia A results from a deficiency in factor VIII activity. Current treatment regimens require frequent dosing, owing to the short half‐life of FVIII.
R. Peters, G. Toby, Qi Lu, Tongyao Liu, J. Kulman, Low Susan, A. Bitonti, Glenn F Pierce   +7 more
semanticscholar   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source